BCR and B-cell chronic lymphocytic leukemia: Due to its hyperactivation in B-cell malignancies and its crucial role in the B-cell receptor (BCR) pathway, it has been approved by FDA in 2014 for the treatment of indolent B-cell malignancies including relapsed/refractory chronic lymphocytic leukaemia (CLL), in association with rituximab, as monotherapy for relapsed follicular lymphoma (FL) and relapsed small lymphocytic leukaemia (SLL), in patients who received at least two prior systemic therapies [79].